maintrac^® - therapy monitoring

Continually determining the number of circulating epithelial tumour cells (CETCs) at regular intervals during cancer therapy makes it possible to monitor the treatment. Following the therapy, the continuing course of the disease can be monitored in the long term by means of the CETCs.

maintrac^®counts and characterises the circulating tumour cells that are present in a patient's blood sample. 15ml EDTA blood is required for this. Only repeated measurement of the CETCs allows an assertion to be made about the tumour activity in the patient. While decreasing cell counts generally signify a successful treatment, an increasing number of CETCs may be an indication of increased tumour activity.